Q3 2025 · 13F-HR
STEMPOINT CAPITAL LPholdings as filed
Filed 2025-11-14 · accession 0001420506-25-003308
$499.1M
Reported value
87
Positions
2025-09-30
Period end
The Brief · STEMPOINT CAPITAL LP · Q3 2025
AI · grounded in 13F
STEMPOINT CAPITAL LP established a new position in ROIVANT SCIENCES LTD valued at $63.5M. The fund also initiated new stakes in UNIQURE NV for $30.5M and SCHOLAR ROCK HLDG CORP for $27.1M. Additional new positions include IMVT at $25.7M and DNLI at $25.2M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $63.5M | 12.7% | 4,197,187 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $30.5M | 6.11% | 522,155 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $27.0M | 5.42% | 726,204 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $25.6M | 5.13% | 1,589,580 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $25.2M | 5.05% | 1,734,659 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $21.0M | 4.21% | 1,366,205 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $15.9M | 3.18% | 655,385 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $15.4M | 3.09% | 2,110,152 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $15.3M | 3.06% | 1,017,311 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $14.6M | 2.92% | 152,325 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $14.1M | 2.83% | 166,273 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $10.1M | 2.03% | 371,825 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $9.2M | 1.85% | 91,444 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $9.2M | 1.84% | 12,465 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $9.2M | 1.84% | 713,463 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $8.7M | 1.73% | 185,380 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $8.6M | 1.73% | 917,630 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $7.8M | 1.56% | 545,275 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $7.8M | 1.56% | 411,893 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $7.7M | 1.55% | 2,488,685 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $7.7M | 1.55% | 192,295 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $7.2M | 1.45% | 241,637 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $6.8M | 1.35% | 136,710 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $6.6M | 1.33% | 127,435 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $6.3M | 1.25% | 43,419 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $6.0M | 1.20% | 474,612 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $6.0M | 1.20% | 158,112 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $5.8M | 1.16% | 121,410 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $5.1M | 1.03% | 39,072 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $5.0M | 1.00% | 114,053 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $4.3M | 0.86% | 150,573 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $4.2M | 0.84% | 359,470 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $3.8M | 0.75% | 8,207 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $3.8M | 0.75% | 276,884 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $3.7M | 0.74% | 43,754 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $3.6M | 0.73% | 129,335 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $3.2M | 0.64% | 350,710 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $3.2M | 0.64% | 47,954 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $3.0M | 0.61% | 53,201 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $3.0M | 0.60% | 15,149 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $3.0M | 0.59% | 188,999 | Common | SOLE |
| 415858109 | HROW | HARROW INC | $2.8M | 0.56% | 57,619 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $2.7M | 0.55% | 839,669 | Common | SOLE |
| 29446K106 | EQ | EQUILLIUM INC | $2.7M | 0.55% | 1,908,935 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $2.6M | 0.53% | 6,264 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $2.5M | 0.51% | 63,019 | Common | SOLE |
| 46090E103 | QQQ | INVESCO QQQ TR | $2.3M | 0.46% | 3,797 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $2.2M | 0.43% | 186,614 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $2.1M | 0.41% | 245,378 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $2.0M | 0.40% | 166,461 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $1.9M | 0.38% | 555,411 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $1.8M | 0.36% | 389,189 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $1.7M | 0.34% | 66,130 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $1.6M | 0.33% | 41,382 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $1.6M | 0.32% | 150,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $1.6M | 0.32% | 363,666 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.6M | 0.32% | 275,620 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $1.5M | 0.31% | 689,538 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $1.3M | 0.26% | 75,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $1.2M | 0.24% | 480,000 | CALL | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $1.1M | 0.23% | 283,286 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $933,970 | 0.19% | 11,376 | Common | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $932,462 | 0.19% | 205,388 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $906,356 | 0.18% | 76,875 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $905,625 | 0.18% | 172,500 | CALL | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $900,072 | 0.18% | 75,194 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $860,072 | 0.17% | 38,742 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $805,756 | 0.16% | 424,082 | Common | SOLE |
| 78464A870 | XBI | SPDR SERIES TRUST | $725,352 | 0.15% | 1,490,100 | PUT | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $710,755 | 0.14% | 96,439 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $691,459 | 0.14% | 56,770 | Common | SOLE |
| G59665102 | MGTX | MEIRAGTX HLDGS PLC | $673,691 | 0.13% | 81,858 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $673,024 | 0.13% | 89,617 | Common | SOLE |
| 03969T109 | ARCT | ARCTURUS THERAPEUTICS HLDGS | $656,219 | 0.13% | 35,606 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $520,832 | 0.10% | 167,470 | Common | SOLE |
| N0731H103 | ATAI | ATAI LIFE SCIENCES NV | $402,209 | 0.08% | 76,032 | Common | SOLE |
| 18507C103 | CLPT | CLEARPOINT NEURO INC | $362,825 | 0.07% | 16,651 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $306,469 | 0.06% | 278,608 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $178,471 | 0.04% | 30,824 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $137,500 | 0.03% | 50,000 | CALL | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $59,000 | 0.01% | 40,000 | CALL | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $55,000 | 0.01% | 100,000 | CALL | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $50,000 | 0.01% | 250,000 | CALL | SOLE |
| 00214Q302 | ARKG | ARK ETF TR | $30,000 | 0.01% | 200,000 | CALL | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $23,920 | 0.00% | 18,400 | CALL | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $9,688 | 0.00% | 15,500 | PUT | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $9,500 | 0.00% | 95,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.